Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

As reported by Share Market Today

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Share Market Today ↗

Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.

INDIAN Dilip Buildcon bags project for establishment of 400 KV Gis Solapur/ Paranda Switching Station Share Market Today
INDIAN HEG Advanced Materials gains on Rs 218 crore lithium-ion battery bank orders Share Market Today
INDIAN Sree Rayalaseema Hi-Strength Hypo Ltd leads gainers in 'B' group Share Market Today
GLOBAL How to trade TCS, Tata Chemicals, other Tata stocks as boardroom battles could reach court economictimes.indiatimes.com
COMPANIES FIIs raise stakes in 14 stocks in Q1; shares rally up to 75% in less than 3 months Stocks-Markets-Economic Times
INDIAN 125% rally in six months | Apparel stock retraces after hitting 52-week high mint - markets
INDIAN GAIL Gas begins process to appoint bankers for up to ₹3,100 crore IPO mint - markets
CRYPTO ZetaChain holders approve plan to wind down L1, move ZETA to Solana Cointelegraph.com News

Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

More from Market Samachar